N,N-dimethyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)ethan-1-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: N,N-dimethyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)ethan-1-amine
• 英文别名: 1-(2-dimethylamino-ethyl)-2-methyl-1H-benzimidazole；1-(2-Dimethylamino-aethyl)-2-methyl-1H-benzimidazol；N,N-dimethyl-2-(2-methylbenzimidazol-1-yl)ethanamine
• 化学式: C₁₂H₁₇N₃
• 分子量: 203.287
• InChiKey: WQYNEUJFMUEPSS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  21.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-(2-二甲基氨基)乙基-2-硝基苯胺 在 盐酸 、 tin(ll) chloride 作用下， 生成 N,N-dimethyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)ethan-1-amine
  参考文献：
  名称：

  Histamine Antagonists. V. Some 1-(β-Dimethylaminoethyl)-benzimidazole Derivatives

  摘要：

  DOI：

  10.1021/ja01174a038

文献信息

• [EN] ANTIBIOTIC COMPOUNDS, PHARMACEUTICAL FORMULATIONS THEREOF AND METHODS AND USES THEREFOR<br/>[FR] COMPOSÉS ANTIBIOTIQUES, LEURS FORMULATIONS PHARMACEUTIQUES, AINSI QUE PROCÉDÉS ASSOCIÉS ET UTILISATIONS ASSOCIÉES
  申请人：UNIV FRASER SIMON

  公开号：WO2017075694A1

  公开（公告）日：2017-05-11

  The present invention relates to compounds of formula (I) wherein G1 to G8 are as defined herein. The compounds are PK inhibitors and as such represent a new approach to treating pathogenic infections, including multidrug resistant pathogens. Disclosed herein are the compounds of formula (I), pharmaceutical compositions comprising the compounds of formula (I) and their use in the treatment of antimicrobial infection. (Formula (1))

  本发明涉及式(I)的化合物，其中G1至G8如本文所定义。这些化合物是PK抑制剂，因此代表了治疗病原体感染的新方法，包括多药耐药病原体。本文披露了式(I)的化合物，包括含有式(I)的药物组合物以及它们在抗微生物感染治疗中的应用。
• N-substituted indoles and other heterocycles for treating brain disorders
  申请人：The Regents of the University of California

  公开号：US11254640B2

  公开（公告）日：2022-02-22

  The present invention provides N-substituted indoles and other heterocycles and methods of using the compounds for treating brain disorders.

  本发明提供了 N-取代吲哚和其他杂环化合物以及使用这些化合物治疗脑部疾病的方法。
• [EN] N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS<br/>[FR] INDOLES N-SUBSTITUÉS ET AUTRES HÉTÉROCYCLES DESTINÉS AU TRAITEMENT DES TROUBLES DU CERVEAU
  申请人：UNIV CALIFORNIA

  公开号：WO2020176597A9

  公开（公告）日：2021-08-05
• ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS
  申请人：GLENMARK PHARMACEUTICALS S.A.

  公开号：US20170022195A1

  公开（公告）日：2017-01-26

  The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein Ring A, Ring B, R, R 2 , R 3 , n, and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (RORγt). These compounds prevent, inhibit, or suppress the action of RORγt and are therefore useful in the treatment of RORγt mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.
• N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS
  申请人：The Regents of the University of California

  公开号：US20210332012A1

  公开（公告）日：2021-10-28

  The present invention provides N-substituted indoles and other heterocycles and methods of using the compounds for treating brain disorders.